Bernzott Capital Advisors’s Royalty Pharma RPRX Stock Holding History

Bernzott Capital Advisors’s Portfolio RPRX Stock Details RPRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-175,365	Closed	-$6.93M	–	53
2022 Q4	$6.93M	Sell	175,365 -5,258	-3%	-$219K	0.9%	41
2022 Q3	$7.26M	Buy	+180,623	New	+$7.72M	1%	42

Other funds holding RPRX

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Bernzott Capital Advisors's RPRX Position: Q1 2023 in Review

Bernzott Capital Advisors sold out of Royalty Pharma (RPRX) in Q1 2023, closing a stake of 175,365 shares — an estimated $6.93M sold.

Bernzott Capital Advisors first reported a position in RPRX in Q3 2022 and held it in 2 quarters. The position peaked at $7.26M in Q3 2022. 335 funds tracked by Wall St. Rank hold RPRX as of Q1 2023.

Bernzott Capital Advisors reported no remaining Royalty Pharma position as of Q1 2023 after selling out during the quarter.
Bernzott Capital Advisors sold 175,365 Royalty Pharma shares in Q1 2023, an estimated $6.93M.
Bernzott Capital Advisors first reported a position in Royalty Pharma in Q3 2022 and held it in 2 quarters.
Bernzott Capital Advisors's Royalty Pharma position peaked at $7.26M in Q3 2022.
335 funds tracked by Wall St. Rank held Royalty Pharma as of Q1 2023.

Based on Bernzott Capital Advisors's 13F filing for Q1 2023, filed 27 Apr 2023.